Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Papachristofilou A, Kallen K, Fotin-Mleczek M, Schröder A, Scheel B, Muth A, Seibel T, Stosnach C, Doener F, Hong H, Koch S, Gnad-Vogt U, Griesinger F, Geißler M, Bischoff H, Hipp M, Klinkhardt U, Früh M, Sebastian M, Weiss C, Pless M, Cathomas R, Hilbe W, Pall G, Wehler T, Alt J, Zippelius A. Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer. J Immunother Cancer 2019; 7:38.
Feb 8, 2019
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
Feb 8, 2019
J Immunother Cancer 2019; 7:38
Papachristofilou Alexandros, Kallen Karl-Josef, Fotin-Mleczek Mariola, Schröder Andreas, Scheel Birgit, Muth Anke, Seibel Tobias, Stosnach Claudia, Doener Fatma, Hong Henoch S, Koch Sven D, Gnad-Vogt Ulrike, Griesinger Frank, Geißler Michael, Bischoff Helge, Hipp Madeleine M, Klinkhardt Ute, Früh Martin, Sebastian Martin, Weiss Christian, Pless Miklos, Cathomas Richard, Hilbe Wolfgang, Pall Georg, Wehler Thomas, Alt Jürgen, Zippelius Alfred
more
